Discover more about the comorbidities of NASH / NAFLD through articles on NASH commentary content ▶ from a study obtained from expert doctors worldwide.
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Over the past few decades, non-alcoholic fatty liver disease (NAFLD) has become a growing problem, alongside the increasing rates of obesity and type 2 diabetes.
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).